このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Insulet 将来の成長

Future 基準チェック /26

Insulet利益と収益がそれぞれ年間3.2%と14.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に19.4% 1.3%なると予測されています。

主要情報

2.4%

収益成長率

0.5%

EPS成長率

Medical Equipment 収益成長	17.5%
収益成長率	14.3%
将来の株主資本利益率	20.5%
アナリストカバレッジ	Good
最終更新日	04 Sep 2024

今後の成長に関する最新情報

Recent updates

Additional Considerations Required While Assessing Insulet's (NASDAQ:PODD) Strong Earnings

Aug 16

A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Jul 15

Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023

Jun 11

We Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)

May 26

At US$166, Is It Time To Put Insulet Corporation (NASDAQ:PODD) On Your Watch List?

May 12

Is Insulet (NASDAQ:PODD) A Risky Investment?

Apr 29

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Apr 14

Estimating The Fair Value Of Insulet Corporation (NASDAQ:PODD)

Mar 31

Insulet: Insulating Patients, Investors Still Have To Wait

Mar 28

Insulet (NASDAQ:PODD) Is Doing The Right Things To Multiply Its Share Price

Feb 19

Is Insulet Corporation (NASDAQ:PODD) Potentially Undervalued?

Jan 22

Insulet: An Interesting, Yet Expensive, Story

Jan 10

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Jan 09

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Dec 27

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Nov 14

Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue

Oct 31

We Think Insulet (NASDAQ:PODD) Is Taking Some Risk With Its Debt

Oct 01

Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?

Sep 16

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Aug 14

Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

Jul 31

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Jun 18

Getting In Cheap On Insulet Corporation (NASDAQ:PODD) Might Be Difficult

May 22

Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

Apr 30

Here's Why Insulet (NASDAQ:PODD) Has A Meaningful Debt Burden

Jan 24

Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue

Dec 28

業績と収益の成長予測

NasdaqGS:PODD - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2,795	365	439	548	17
12/31/2025	2,380	286	357	455	21
12/31/2024	2,015	379	280	397	21
6/30/2024	1,873	395	182	285	N/A
3/31/2024	1,781	234	137	233	N/A
12/31/2023	1,697	206	37	146	N/A
9/30/2023	1,557	120	-15	151	N/A
6/30/2023	1,465	63	-26	152	N/A
3/31/2023	1,368	1	-45	133	N/A
12/31/2022	1,305	5	-38	119	N/A
9/30/2022	1,243	17	-63	43	N/A
6/30/2022	1,178	35	-141	-40	N/A
3/31/2022	1,142	45	-152	-47	N/A
12/31/2021	1,099	17	-191	-68	N/A
9/30/2021	1,037	-29	-199	-26	N/A
6/30/2021	996	-30	-126	44	N/A
3/31/2021	959	9	-120	53	N/A
12/31/2020	904	7	-82	84	N/A
9/30/2020	868	29	-15	114	N/A
6/30/2020	826	18	-25	101	N/A
3/31/2020	777	5	-65	88	N/A
12/31/2019	738	12	-72	98	N/A
9/30/2019	694	17	-74	82	N/A
6/30/2019	653	17	-103	67	N/A
3/31/2019	600	14	-126	47	N/A
12/31/2018	564	3	-126	36	N/A
9/30/2018	529	-13	-130	27	N/A
6/30/2018	500	-17	-93	35	N/A
3/31/2018	486	-23	N/A	59	N/A
12/31/2017	464	-27	N/A	41	N/A
9/30/2017	437	-29	N/A	39	N/A
6/30/2017	410	-30	N/A	19	N/A
3/31/2017	387	-26	N/A	5	N/A
12/31/2016	367	-27	N/A	16	N/A
9/30/2016	347	-34	N/A	-23	N/A
6/30/2016	324	-49	N/A	-17	N/A
3/31/2016	297	-62	N/A	-20	N/A
12/31/2015	264	-62	N/A	-13	N/A
9/30/2015	253	-51	N/A	11	N/A
6/30/2015	256	-44	N/A	7	N/A
3/31/2015	268	-56	N/A	6	N/A
12/31/2014	231	-48	N/A	9	N/A
9/30/2014	285	-49	N/A	1	N/A
6/30/2014	271	-59	N/A	0	N/A
3/31/2014	259	-40	N/A	4	N/A
12/31/2013	247	-45	N/A	3	N/A
9/30/2013	236	-53	N/A	1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PODDの予測収益成長率 (年間2.4% ) は貯蓄率 ( 2.5% ) を下回っています。

収益対市場: PODDの収益 ( 3.2% ) US市場 ( 15.2% ) よりも低い成長が予測されています。

高成長収益: PODDの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: PODDの収益 ( 14.3% ) US市場 ( 8.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: PODDの収益 ( 14.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PODDの自己資本利益率は、3年後には高くなると予測されています ( 20.2 %)

Insulet 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Consensus EPS estimates increase by 18%

Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Consensus EPS estimates increase by 13%

Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Year Ending December 31, 2023

Price target decreased by 8.0% to US$250

Recent updates

Is Insulet (NASDAQ:PODD) A Risky Investment?

Insulet: Turning More Constructive, Valuations Still Stretched

Here's Why We Think Insulet (NASDAQ:PODD) Is Well Worth Watching

Insulet Corporation Announces Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Additional Considerations Required While Assessing Insulet's (NASDAQ:PODD) Strong Earnings

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Insulet Corporation to Report Q2, 2024 Results on Aug 08, 2024

Now 9.0% overvalued after recent price rise

Now 20% overvalued after recent price rise

Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

Independent Chairman recently sold US$1.3m worth of stock

Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023

Independent Chairman notifies of intention to sell stock

We Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)

Investor sentiment improves as stock rises 16%

At US$166, Is It Time To Put Insulet Corporation (NASDAQ:PODD) On Your Watch List?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Is Insulet (NASDAQ:PODD) A Risky Investment?

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation to Report Q1, 2024 Results on May 09, 2024

Estimating The Fair Value Of Insulet Corporation (NASDAQ:PODD)

Insulet: Insulating Patients, Investors Still Have To Wait

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial (RCT) Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)

Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes

Director & Advisor notifies of intention to sell stock

Consensus EPS estimates increase by 18%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Insulet (NASDAQ:PODD) Is Doing The Right Things To Multiply Its Share Price

Is Insulet Corporation (NASDAQ:PODD) Potentially Undervalued?

Insulet Corporation Announces Board Changes

Insulet Corporation to Report Q4, 2023 Results on Feb 22, 2024

Insulet: An Interesting, Yet Expensive, Story

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Director & Advisor recently sold US$2.5m worth of stock

Director & Advisor notifies of intention to sell stock

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Consensus EPS estimates increase by 13%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Year Ending December 31, 2023

Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue

Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone

Price target decreased by 8.0% to US$250

Now 21% undervalued after recent price drop

Insulet Corporation Announces CFO Transition

We Think Insulet (NASDAQ:PODD) Is Taking Some Risk With Its Debt

Insulet Corporation to Report Q3, 2023 Results on Nov 02, 2023

Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?

Insulet Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System in Germany

Consensus EPS estimates increase by 14%

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

Insulet Corporation to Report Q2, 2023 Results on Aug 08, 2023

Insulet Corporation Announces Omnipod 5 Automated Insulin Delivery System Is Now Available in the United Kingdom

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Insider recently bought US$1.0m worth of stock

Getting In Cheap On Insulet Corporation (NASDAQ:PODD) Might Be Difficult

Consensus EPS estimates increase by 10%

Bret Christensen, Executive Vice President, Chief Commercial Officer Will Be Leaving Insulet Corporation

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

Executive VP recently sold US$399k worth of stock